Literature DB >> 301122

Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients: the role of suppressor cells.

M Zembala, B Mytar, T Popiela, G L Asherson.   

Abstract

The reactivity of peripheral blood lymphocytes from patients with advanced malignancy was assessed by mitogen-induced stimulation of protein synthesis as measured by 3H-leucine incorporation. It was confirmed that the lymphocyte response of patients was depressed. Furthermore, the lymphocytes of 15 out of 27 cancer patients, selected because of their low responses, inhibited the reactivity of normal lymphocytes in co-cultures. The lymphocytes from one patient with Hodgkin's disease were also inhibitory. In contrast, lymphocytes from healthy subjects, patients with chronic lymphocytic leukaemia, lymphosarcoma or multiple myeloma caused no suppression. Experiments with purified cell populations from patients with carcinoma indicated that purified T cells responded to mitogens while unseparated lymphocytes failed to respond and that the inhibitory activity was due to adherent cells, presumably monocytes. There was no evidence for B-cell-mediated suppression. However, in two cases inhibition was caused by isolated T cells of the patients and not by adherent cells. These experiments suggested that one mechanism for the depression of cell-mediated immunity seen in patients with advanced cancer may be the nonspecific suppresssion of certain T-cell functions by circulating monocytes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 301122     DOI: 10.1002/ijc.2910190503

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

1.  Enhanced expression of lipocortin-1 as a new immunosuppressive protein in cancer patients and its influence on reduced in vitro peripheral blood lymphocyte response to mitogens.

Authors:  H Koseki; K Shiiba; Y Suzuki; T Asanuma; S Matsuno
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

2.  Reversal of defective lymphoproliferation in postoperative patients with colon cancer.

Authors:  L Schindler; M Leroux; G F Zimmermann; M Betzler; H Kirchner
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Migration inhibition of T lymphocytes from human peripheral blood by specific antigen and lymphokines.

Authors:  D Kowalczyk; M Zembala
Journal:  Clin Exp Immunol       Date:  1978-05       Impact factor: 4.330

4.  Immune defects in chronic renal impairment: evidence for defective regulation of lymphocyte response by macrophages from patients with chronic renal impairment on haemodialysis.

Authors:  N D Tsakolos; T C Theoharides; E D Hendler; J Goffinet; J M Dwyer; R L Whisler; P W Askenase
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

5.  Immunogenetic studies in retinoblastoma.

Authors:  D F Roberts; M Duggan-Keen; G E Aherne; D R Long
Journal:  Br J Ophthalmol       Date:  1986-09       Impact factor: 4.638

6.  The effect of major surgery on T-lymphocyte function in patients with gastrointestinal cancer.

Authors:  J P Duignan; A H Johnson; P B Collins; D Bouchier-Hayes
Journal:  Ir J Med Sci       Date:  1987-04       Impact factor: 1.568

7.  In vitro proliferation of macrophage depleted human peripheral blood lymphocytes.

Authors:  A J Treves; V Barak; Z Fuks
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

8.  Decreased interleukin generation in patients with cancer of the digestive system. A correlation between interleukin 1 and interleukin 2 production.

Authors:  Y Haga; K Sakamoto; Y Yokoyama; M Akagi
Journal:  Jpn J Surg       Date:  1988-09

9.  Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells.

Authors:  G W Wood; R A Morantz
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

10.  Lymphocyte cyclic AMP levels in primary hypogammaglobulinaemia: lack of correlation with response to phytohaemagglutinin.

Authors:  A D Webster; M E North; C Newton; G L Asherson
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.